# CIML NK Cells With Venetoclax for AML

> **NCT06152809** · PHASE1 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 10 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Recurrent
- Leukemia
- Leukemia, Myeloid

## Interventions

- **BIOLOGICAL:** Cytokine-Induced Memory-like Natural Killer Cells
- **BIOLOGICAL:** Interleukin-2
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06152809
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2026-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06152809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06152809, "CIML NK Cells With Venetoclax for AML". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06152809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*